Kennedy Capital Management LLC Purchases 29,484 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Kennedy Capital Management LLC raised its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 8.1% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 394,026 shares of the biopharmaceutical company's stock after acquiring an additional 29,484 shares during the period. Kennedy Capital Management LLC owned about 0.31% of Halozyme Therapeutics worth $18,838,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in the business. Venturi Wealth Management LLC purchased a new position in Halozyme Therapeutics in the 4th quarter worth $69,000. Retirement Systems of Alabama increased its holdings in shares of Halozyme Therapeutics by 23.5% in the third quarter. Retirement Systems of Alabama now owns 389,268 shares of the biopharmaceutical company's stock worth $22,282,000 after buying an additional 74,173 shares during the period. Shaker Investments LLC OH lifted its stake in shares of Halozyme Therapeutics by 12.3% in the 4th quarter. Shaker Investments LLC OH now owns 75,326 shares of the biopharmaceutical company's stock valued at $3,601,000 after acquiring an additional 8,249 shares during the last quarter. Foster & Motley Inc. boosted its holdings in Halozyme Therapeutics by 118.6% during the 4th quarter. Foster & Motley Inc. now owns 23,280 shares of the biopharmaceutical company's stock valued at $1,113,000 after acquiring an additional 12,630 shares during the period. Finally, Jennison Associates LLC bought a new position in Halozyme Therapeutics during the 4th quarter worth approximately $731,000. 97.79% of the stock is currently owned by institutional investors.

Remove Ads

Halozyme Therapeutics Stock Down 0.4 %

Shares of NASDAQ:HALO traded down $0.24 during midday trading on Tuesday, reaching $61.15. The company's stock had a trading volume of 265,714 shares, compared to its average volume of 1,408,210. Halozyme Therapeutics, Inc. has a 12-month low of $37.73 and a 12-month high of $66.00. The firm has a market capitalization of $7.55 billion, a P/E ratio of 17.83, a PEG ratio of 0.42 and a beta of 1.32. The firm has a 50 day moving average of $60.29 and a 200-day moving average of $54.94. The company has a quick ratio of 9.15, a current ratio of 7.80 and a debt-to-equity ratio of 4.14.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last released its earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.17 by $0.02. The firm had revenue of $298.01 million during the quarter, compared to analyst estimates of $285.74 million. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. On average, research analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current year.

Insider Activity

In other news, SVP Michael J. Labarre sold 1,697 shares of the company's stock in a transaction on Thursday, February 27th. The stock was sold at an average price of $58.28, for a total transaction of $98,901.16. Following the transaction, the senior vice president now directly owns 173,756 shares of the company's stock, valued at $10,126,499.68. This represents a 0.97 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Jeffrey William Henderson sold 5,000 shares of Halozyme Therapeutics stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $56.30, for a total value of $281,500.00. Following the completion of the sale, the director now owns 38,611 shares of the company's stock, valued at $2,173,799.30. The trade was a 11.46 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 22,200 shares of company stock worth $1,286,568 over the last three months. 2.40% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the company. Piper Sandler boosted their price objective on Halozyme Therapeutics from $52.00 to $53.00 and gave the company a "neutral" rating in a research report on Friday, January 10th. Benchmark reiterated a "buy" rating and set a $75.00 price target on shares of Halozyme Therapeutics in a report on Thursday, February 20th. Wells Fargo & Company cut their price target on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating on the stock in a report on Monday, January 13th. Finally, HC Wainwright reaffirmed a "buy" rating on shares of Halozyme Therapeutics in a research note on Thursday, March 6th. Four investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat.com, Halozyme Therapeutics has an average rating of "Moderate Buy" and an average target price of $62.78.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.